A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.
Status:
Not yet recruiting
Trial end date:
2022-08-20
Target enrollment:
Participant gender:
Summary
The study is being conducted to assess the efficacy and safety of SHR6390 combined with
famitinib in the treatment of advanced or metastatic breast cancer that progress in 1-2 line
endocrine therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital